Some of Ms. Luo’s representative matters include:
- 5AM Ventures in its investment in a computational genomics company focused on identifying inherited disease risk in future generations and in a digital therapeutics company for enhanced clinical outcomes
- A healthcare venture firm in multiple rounds of investment in an oral healthcare company that develops, acquires and commercializes oral health care technologies
- Action Pharma, a privately owned Danish biotech company, in its $110 million sale to Abbott Laboratories
- Axcella Health, a biotechnology company pioneering first-in-class medicines for serious conditions linked to amino acid imbalances, in multiple financing rounds, including its $42.5 million Series D financing
- Endeca Technologies, a provider of unstructured data management, web commerce and business intelligence solutions, in its sale to Oracle
- ExtendMedia, a provider of software-based content management systems, in its sale to Cisco
- Lycera Corp. in its collaboration and buyout option transaction with Celgene Corporation with a value of up to $105 million
- Moderna Therapeutics, a biotechnology company that researches and develops protein therapies based on mRNA technology, in multiple financing rounds, including its $110 million Series D financing and $500 million Series E financing
- Ra Pharmaceuticals, a clinical stage biopharma developing a treatment for PNH, a rare orphan disease, in its $8 million Series A financing and $58.5 million Series B financing
- The underwriters in the $50.9 million initial public offering, and subsequent follow-on offering, of a specialty pharmaceutical company focusing on the development and commercialization of products for treating central nervous system disorders
- The underwriters in the $58 million follow-on offering of an international pharmaceutical company focusing on the development and commercialization of ancillary hemodialysis products
